After a two-month battle, OSI Pharmaceuticals said on Sunday that it had agreed to sell itself to Astellas Pharma of Japan for US$4 billion in cash, after its suitor raised its takeover offer.
Under the terms of the deal, OSI shareholders will receive US$57.50 a share, a 55 percent premium to OSI’s share price on Feb. 26, the last trading day before Astellas made its first takeover bid public in March.
The new price is 10.5 percent higher than Astellas’ first proposal of US$52 a share.
The sale ends a standoff over OSI, a biotechnology company whose main product is Tarceva, a drug used to treat several kinds of cancer in conjunction with chemotherapy.
Astellas initially unveiled a US$3.5 billion unsolicited offer in March, which OSI rejected soon after.
After Astellas began a tender offer for OSI’s shares and proposed a rival slate of directors, the US drug maker agreed to open its books to its unsolicited suitor.
Analysts have said that they expected Astellas to prevail, especially given an apparent paucity of rival bidders. But they expected that Astellas would need to raise its bid.
Shares in OSI closed on Friday at US$59.80, up nearly 4.5 percent, as investors expected Astellas to raise its offer for the company. OSI’s stock has risen 61.5 percent since Astellas made its first takeover proposal.
Colin Goddard, OSI’s chief executive, said in a statement: “We believe today’s announcement recognizes the significant value we have built for our stockholders while providing the merged companies the opportunity to forge a stronger collective path forward in a shared mission to provide innovative new medicines to patients around the world.”
Founded in 1983 and based in Melville, New York, OSI’s main product is Tarceva, primarily used to treat lung cancer. The drug generated US$1.2 billion in sales last year. OSI has sought to expand Tarceva’s use in cancer treatment.
The company reported US$75.9 million in net income last year, on US$428.1 million in revenue. It has 524 employees.
Astellas, based in Tokyo and one of Japan’s biggest drug makers, has made it clear that a priority was expanding its oncology drug pipeline.
The deal is a successful effort by Astellas to buy a US biotech company, after losing a battle over CV Therapeutics last year to Gilead Sciences.
“The merger with OSI provides Astellas with a top tier oncology platform in the US and an expanded product portfolio and pipelines,” Astellas chief executive Masafumi Nogimori said in a statement.
QUIET START: Nearly a week after applications opened, agencies did not announce or promote the program, nor did they explain how it differed from other visitor visas Taiwan has launched a six-month “digital nomad visitor visa” program for foreign nationals from its list of visa-exempt countries who meet financial eligibility criteria and provide proof of work contracts. To apply, foreign nationals must either provide proof that they have obtained a digital nomad visa issued by another country or demonstrate earnings based on age brackets, the Bureau of Consular Affairs said. Applicants aged 20 to 29 must show they earned an annual salary of at least US$20,000 or its equivalent in one of the past two years, while those aged 30 or older must provide proof they earned US$40,000 in
AIR DEFENSE: The Norwegian missile system has proved highly effective in Ukraine in its war against Russia, and the US has recommended it for Taiwan, an expert said The Norwegian Advanced Surface-to-Air Missile Systems (NASAMS) Taiwan ordered from the US would be installed in strategically important positions in Taipei and New Taipei City to guard the region, the Ministry of National Defense said in statement yesterday. The air defense system would be deployed in Taipei’s Songshan District (松山) and New Taipei City’s Tamsui District (淡水), the ministry said, adding that the systems could be delivered as soon as the end of this year. The US Defense Security Cooperation Agency has previously said that three NASAMS would be sold to Taiwan. The weapons are part of the 17th US arms sale to
SERIOUS ALLEGATIONS: The suspects formed spy networks and paramilitary groups to kill government officials during a possible Chinese invasion, prosecutors said Prosecutors have indicted seven retired military officers, members of the Rehabilitation Alliance Party, for allegedly obtaining funds from China, and forming paramilitary groups and assassination squads in Taiwan to collaborate with Chinese troops in a possible war. The suspects contravened the National Security Act (國家安全法) by taking photos and drawing maps of key radar stations, missile installations and the American Institute in Taiwan’s headquarters in Taipei, prosecutors said. They allegedly prepared to collaborate with China during a possible invasion of Taiwan, prosecutors said. Retired military officer Chu Hung-i (屈宏義), 62, a Republic of China Army Academy graduate, went to China
UNITY MESSAGE: Rather than focusing on what Trump said on the campaign trail about Taiwan, Taipei should be willing to engage with the US, Pompeo said Taiwan plays a key role in Washington’s model of deterrence against China, former US secretary of state Mike Pompeo said in a speech in Taipei yesterday. During US president-elect Donald Trump’s first term, “we had developed what we believe was a pretty effective model of deterrence against adversaries who wanted to undermine the set of rules and values that the people of Taiwan and the people of the US hold dear,” Pompeo said at a forum organized by the Formosa Republican Association. “Succeeding in continuing to build this model will not solely rest at the feet of president Trump and his team,
RSS